JP2008522955A5 - - Google Patents

Download PDF

Info

Publication number
JP2008522955A5
JP2008522955A5 JP2007526862A JP2007526862A JP2008522955A5 JP 2008522955 A5 JP2008522955 A5 JP 2008522955A5 JP 2007526862 A JP2007526862 A JP 2007526862A JP 2007526862 A JP2007526862 A JP 2007526862A JP 2008522955 A5 JP2008522955 A5 JP 2008522955A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
ylthio
pitavastatin
benzimidazol
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007526862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008522955A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2005/023088 external-priority patent/WO2006064889A1/en
Publication of JP2008522955A publication Critical patent/JP2008522955A/ja
Publication of JP2008522955A5 publication Critical patent/JP2008522955A5/ja
Pending legal-status Critical Current

Links

JP2007526862A 2004-12-10 2005-12-09 リピド・リッチ・プラークの縮小、安定化及び破裂予防方法 Pending JP2008522955A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63453204P 2004-12-10 2004-12-10
PCT/JP2005/023088 WO2006064889A1 (en) 2004-12-10 2005-12-09 Method for reduction, stabilization and prevention of rupture of lipid rich plaque

Publications (2)

Publication Number Publication Date
JP2008522955A JP2008522955A (ja) 2008-07-03
JP2008522955A5 true JP2008522955A5 (enExample) 2008-10-16

Family

ID=36587943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007526862A Pending JP2008522955A (ja) 2004-12-10 2005-12-09 リピド・リッチ・プラークの縮小、安定化及び破裂予防方法

Country Status (11)

Country Link
US (2) US20090275595A1 (enExample)
EP (1) EP1827440A4 (enExample)
JP (1) JP2008522955A (enExample)
KR (1) KR100895031B1 (enExample)
CN (1) CN101068548B (enExample)
AU (1) AU2005314810B2 (enExample)
CA (1) CA2590224C (enExample)
NZ (1) NZ554924A (enExample)
RU (1) RU2351337C1 (enExample)
TW (1) TW200619204A (enExample)
WO (1) WO2006064889A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2358734C2 (ru) * 2003-08-29 2009-06-20 Кова Ко., Лтд. Способ стабилизации бляшки с высоким содержанием липидов и способ профилактики ее разрушения
US8048083B2 (en) * 2004-11-05 2011-11-01 Dfine, Inc. Bone treatment systems and methods
EP2520299A1 (en) * 2009-12-29 2012-11-07 Kowa Co., Ltd. Solid pharmaceutical composition for oral administration
KR20120116422A (ko) * 2009-12-29 2012-10-22 코와 가부시키가이샤 경구 투여용 의약 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CN1217656C (zh) * 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
CN1118457C (zh) * 1997-05-26 2003-08-20 兴和株式会社 新的环状二胺化合物及含有它的药物
US6969711B2 (en) * 1997-05-26 2005-11-29 Kowa Company, Ltd. Cyclic diamine compounds and medicine containing the same
RU2235483C2 (ru) * 1998-11-25 2004-09-10 Нутри Фарма Аса Композиция, фармацевтический препарат и способ для профилактики и/или лечения и/или ослабления сердечно-сосудистых заболеваний
AU7717500A (en) * 1999-09-30 2001-04-30 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
HUP0302825A3 (en) * 2000-07-13 2005-02-28 Takeda Pharmaceutical Lipid-rich plaque inhibitors
WO2002020009A1 (en) * 2000-09-01 2002-03-14 Sankyo Company, Limited Medicinal compositions
US20060165605A1 (en) * 2001-12-28 2006-07-27 Ye-Mon Chen Process to regenerate fcc spent catalyst
MY140618A (en) * 2003-02-28 2009-12-31 Kowa Co Method for preparing acid addition salts of polyacidic basic compounds
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia

Similar Documents

Publication Publication Date Title
JP2015528471A5 (enExample)
JP2015512406A5 (enExample)
JP2006508953A5 (enExample)
JP2018168191A5 (enExample)
JP2004512328A5 (enExample)
JP2007514750A5 (enExample)
JP2002528502A5 (enExample)
JP2014515373A5 (enExample)
ES2489265T3 (es) Asociación de inhibidores de la HMG-CoA reductasa atorvastatina o simvastatina con un inhibidor de la fosfodiesterasa 4, tal como roflumilast para el tratamiento de enfermedades pulmonares inflamatorias
CN104023715B (zh) 激酶抑制剂的副作用降低剂
JP2009513713A5 (enExample)
JP2007532607A5 (enExample)
JP2009062388A5 (enExample)
TWI351950B (en) Use of (halobenzyloxy) benzylamino-propanamides fo
JP2005508963A5 (enExample)
JP2004532828A5 (enExample)
JP2005513014A5 (enExample)
RU2014112324A (ru) Применение органического соединения для лечения синдрома нунан
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
JP2008522955A5 (enExample)
JP2002534477A5 (enExample)
RU2006110035A (ru) Способ стабилизации бляшки с высоким содержанием липидов и способ профилактики ее разрушения
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物
CA2590224A1 (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
JP4839309B2 (ja) 血栓症治療剤